Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00635232 · ClinicalTrials.gov registry record · Phase 2
A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension
A Phase 2 study, sponsored by Ligand Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 261
- Enrollment target
NCT00635232 is a Phase 2 study that has completed, run by Ligand Pharmaceuticals. The registered enrollment target is 261 participants.
The verdict
NCT00635232, a Phase 2 study, has completed, sponsored by Ligand Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 261 participants
- Enrollment target
Study Summary
The purpose of this study is to learn which doses of PS433540 should be given to patients with high blood pressure to lower their blood pressure. This study will also examine how safe PS433540 is when taken by patients with high blood pressure. Approximately 720 patients will be evaluated so that about 375 patients will be entered into the treatment phase of the study and be given PS433540.
Interventions
- DRUG placebo
- DRUG irbesartan
- DRUG PS433540
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00635232
The ClinicalTrials.gov registry entry for NCT00635232 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 261 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ligand Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00635232 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00635232 about?
NCT00635232 is a clinical study titled "A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension". The purpose of this study is to learn which doses of PS433540 should be given to patients with high blood pressure to lower their blood pressure. This study will also examine how safe PS433540 is when taken by patients with high blood pressure. Approximately 720 patients will be evaluated so that ab...
What is the current status of trial NCT00635232?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 261 participants. The study started on 2008-03. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00635232?
The interventions under investigation include: placebo (DRUG), irbesartan (DRUG), PS433540 (DRUG).
Who is sponsoring clinical trial NCT00635232?
This trial is sponsored by Ligand Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.